Biocon Limited will announce its financial results for the first quarter of FY27 on Wednesday, August 05, 2026, following a scheduled meeting of its Board of Directors. The company will subsequently host an earnings conference call for analysts and investors on Thursday, August 06, 2026, at 10:00 hrs IST to discuss performance for the quarter ended June 30, 2026. This schedule ensures market participants have timely access to management commentary alongside the financial data.

The Board meeting, held pursuant to Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, will approve both standalone and consolidated un-audited results. Alongside these financial approvals, the Board will address other routine matters. The company has notified the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) regarding these proceedings.

In compliance with the Code of Conduct for Prevention of Insider Trading and the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in Biocon’s securities has been closed. The blackout period commenced on Wednesday, July 01, 2026, and will remain in effect until Friday, August 07, 2026, inclusive. Trading will resume on Saturday, August 08, 2026.

The earnings conference call will be conducted over Zoom. Participants are advised to join ten minutes prior to the scheduled start time. Detailed registration information is available on the company’s investor relations website. Following the call, an audio recording will be accessible before the next trading day or within 24 hours, whichever is earlier. A video recording will be available within 48 hours.

Transcripts of the conference call will be published on the company’s website within five working days of its conclusion. All recordings and transcripts can be accessed under the Financial Information section of the Investor Relations page. For further inquiries, investors may contact Prashant Nair from the Investor Relations team.

Regulatory Disclosures

The intimation was signed by Rajesh U. Shanoy, Company Secretary and Compliance Officer, on July 28, 2026. The company includes a safe harbor statement noting that forward-looking statements made during the call involve risks and uncertainties. These include general economic conditions, R&D efforts, currency fluctuations, interest rate changes, and regulatory shifts in the biotechnology and pharmaceuticals sectors. Neither Biocon nor its directors assume an obligation to update these forward-looking statements.

Biocon has secured Notice of Compliance (NOC) from Health Canada for its Yesintek® (ustekinumab) Autoinjector Pen, expanding its biosimilar portfolio in the Canadian market. The approval, announced on July 29, 2026, covers two dosage strengths: 45 mg/0.05 mL and 90 mg/mL. This regulatory milestone adds a convenient self-administration option to Biocon’s existing Yesintek offerings, which include prefilled syringes, vials, and intravenous infusion solutions approved in October 2025. The autoinjector format provides a delivery method not currently offered by the originator product in Canada, allowing for customized treatment approaches across various care settings.

Regulatory Approval Details

The Health Canada approval specifically targets the autoinjector pen formulation of ustekinumab, a biologic therapy used to manage autoimmune conditions. This addition complements the company’s previously approved Yesintek® formulations, including the 45 mg/0.5 mL and 90 mg/mL prefilled syringes and vials, as well as the 130 mg/26 mL intravenous solution. The expansion into autoinjector technology enhances patient convenience and adherence by enabling self-administration.

Clinical Indications and Market Impact

Yesintek® is indicated for the treatment of moderate to severe plaque psoriasis in adult and pediatric patients aged 6 to 17 years. It also treats active psoriatic arthritis in adults, as well as moderately to severely active Crohn’s disease and ulcerative colitis in adults. These autoimmune conditions affect thousands of Canadians, and the availability of an affordable biosimilar alternative strengthens patient access to care. The new autoinjector format addresses a gap in the Canadian market where the originator product does not offer this delivery mechanism, potentially influencing prescribing patterns and patient preference.

Strategic Significance for Biocon

This approval reinforces Biocon’s commitment to expanding its immunology portfolio in regulated markets like Canada. By diversifying its delivery formats, Biocon aims to provide healthcare providers with more flexible treatment options. The company’s spokesperson noted that this development reaffirms its global mission to increase access to affordable medicines. With a growing presence in North America, Biocon continues to leverage its biosimilar expertise to compete with originator biologics, offering cost-effective solutions without compromising efficacy or safety.